Browsing by Author "Koch Hein, Erica Cristina"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Impact of Adjuvant FOLFOX on Quality of Life and Peripheral Neuropathy Incidence in Patients With Gastric Cancer: A Prospective Cohort Study
    (Elsevier Inc., 2023) Mondaca Contreras, Sebastián Patricio; Pinto, Mauricio P.; Briones Carvajal, Juan Rodrigo; Caire, Nicole; Peña Prado, José Tomas; Koch Hein, Erica Cristina; Muñiz Muñoz, Maria Sabrina; Herrera, María Elisa; Sanchez Rojel, Cesar Giovanni; Galindo Aranibar, Héctor Gonzalo; Pizarro Brito, Gonzalo Ignacio; Acevedo Claros, Francisco Nicolas; Ibáñez Cáceres, Carolina; Balmaceda Araque, Carlos Felipe; Norero, Enrique; Duran, Doris; Garrido Salvo, Marcelo Adán; Nervi Nattero, Bruno
    Objectives: Perioperative and adjuvant chemotherapy have demonstrated clinical benefits in localized gastric cancer. Nevertheless, the reports on their effects on patient's health-related quality of life (HRQoL) are scarce. Here, we prospectively assessed quality of life and the incidence of chemotherapy-induced peripheral neuropathy (CIPN) in a cohort of patients treated with adjuvant FOLFOX. Methods: Localized stomach or gastroesophageal junction adenocarcinoma patients who underwent curative resection were recruited at a single center. All patients received adjuvant FOLFOX6, and HRQoL and CIPN were assessed using the European organization for research and treatment of cancer quality life (EORTC) C30 and the EORTC CIPN20 questionnaires, respectively. Clinically significant deterioration of HRQoL was also assessed as a coprimary outcome in a longitudinal analysis. Results: We recruited a total of 63 patients. Median age was 62.5 years, and 75% had stomach tumors. Twenty-four weeks after the start of treatment, the probability of being free from HRQoL deterioration and CIPN was 29% (95% confidence interval [CI] 18%-42%) and 6% (95% CI 2%-17%), respectively. Five-year disease-free survival was 45% (95% CI 24%-64%) and 5-year overall survival was 63% (95% CI 48%-76%). Conclusions: Adjuvant FOLFOX is associated with a high rate of long-term survival in localized gastric cancer; nevertheless, it has detrimental effects on patients’ quality of life.
  • Thumbnail Image
    Item
    Reduction in the number of early melanomas diagnosed during the COVID‐19 pandemic: a single‐centre cohort study
    (2021) Koch Hein, Erica Cristina; Villanueva, Francisco; Marchetti, Michael A.; Abarzúa Araya, Álvaro Rodrigo; Cárdenas de la Torre, Consuelo Paz; Castro, Juan Camilo; Domínguez Covarrubias, Francisco José; Droppelmann, Katherine; Droppelmann, Nicolás; Galindo A., Héctor; León Ramírez, Augusto; Madrid Arenas, Jorge; Molgó Novell, Montserrat; Mondaca, Sebastián; Montero, Pablo H.; Uribe González, Pablo Francisco; Villaseca, Miguel A.; Vinés Vásquez, Eugenio; Navarrete Dechent, Cristian